Our Team

Each Partner brings extensive industry knowledge, unrivaled relationships and substantial deal experience, resulting in a team of the industry's most sought after advisors

Mark J. Robinson


Over his 24-year career, Mr. Robinson has advised many of the most prominent pharmaceutical, biotechnology and medical device companies in the healthcare industry.

Selected assignments while at Centerview include being the adviser to Pharmacyclics on its $21 billion sale to AbbVie, exclusive advisor to Onyx in its $10.4 billion sale to Amgen, advising Intermune on its $8.9 billion sale to Roche, Receptos on its $7.8bn sale to Celgene, Biogen on its defense against Icahn and acquisition of control of Tysabri from Elan, Questcor on its $5.6 billion merger with Mallinckrodt, OSI on its hostile defense and $4 billion sale to Astellas, Idenix in its $3.8 billion sale to Merck, Avanir in its $3.5 billion sale to Otsuka, Relypsa in its $1.5 billion sale to Galenica and Tobira in its sale for up to $1.7 billion to Allergan.

Prior to Centerview, Mr. Robinson spent 12 years at Merrill Lynch in San Francisco where he had been Global Co-Head of Healthcare Investment Banking for the last six of those years.  Notable historic landmark transactions include advising Immunex in its $16 billion sale to Amgen and IDEC in its $7 billion merger with Biogen to create Biogen Idec, Vertex in its acquisition of Aurora and Illumina in its purchase of Solexa. At the time of his departure from Merrill Lynch, Mr. Robinson had been involved in raising more capital for biotechnology companies than anyone in the history of the industry. Mr. Robinson joined Merrill Lynch in 1998 to build the biotechnology and medical devices investment banking efforts after working at CS First Boston and Robertson Stephens.

Mr. Robinson currently is Chairman of the Board of the College of Letters and Science at U.C. Berkeley and on the Board of Trustees of the U.C. Berkeley Foundation and The Thacher School. He is also a member of the Council on Foreign Relations.


Mr. Robinson received his B.A. from the University of California Berkeley and an M.B.A. from Harvard Business School.

Centerview Partners takes a “One Firm” approach to deliver unmatched intellectual capital and integrity to all of our clients. We have industry-leading expertise in:

Centerview is honored to partner with leading charitable organizations in active support of our charities:

  • Arts Connection
  • NY Cares
  • Bottomless Closet
Gilead Sceinces, Inc.
Announced: Q3 2019
Value: $5.1 billion
Status: Pending

Financial advisor to Gilead on its 10-year global R&D collaboration with Galapagos NV
View All
New York

Centerview Partners LLC
31 West 52nd Street
22nd Floor
New York, New York 10019

(212) 380-2650 | Tel
(212) 380-2651 | Fax

Centerview Partners UK LLP
100 Pall Mall
3rd Floor
London SW1Y 5NQ,

02074099700 | Tel
02074099704 | Fax
San Francisco

Centerview Partners LLC
555 California Street
Suite 4300
San Francisco, CA 94104

(415) 400-0900 | Tel
(415) 400-0901 | Fax
Los Angeles

Centerview Partners LLC
1999 Avenue of the Stars
Suite 3030
Los Angeles, CA 90067

(424) 230-5950 | Tel
(424) 230-5951 | Fax
Palo Alto

Centerview Partners LLC
600 Ramona St.
Suite 300
Palo Alto, California 94301

(650) 822-5800 | Tel
(650) 822-5801 | Fax

Copyright © 2008 - 2019 Centerview Partners Holdings LP. All Rights Reserved. | Privacy and Other Notices

Centerview Partners LLC, member SIPC